Halozyme Therapeutics | HALO - Ordinary Share Capital


Halozyme Therapeutics reported $117.78M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Agios Pharmaceuticals USD 58.45M 169K Dec/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Amarin USD 20.81M 13K Dec/2025
Amgen USD 539M 1000K Dec/2025
Baxter International USD 514.28M 168.72M Dec/2025
Cara Therapeutics USD 9.38M 9.38M Sep/2025
Cytokinetics USD 122.26M 145K Dec/2025
DBV Technologies USD 136.82M 51.98K Sep/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
Halozyme Therapeutics USD 117.78M 259K Dec/2025
Intrexon USD 0 0 Jun/2024
Ionis Pharmaceuticals USD 161.97M 836K Dec/2025
MannKind USD 307.83M 806K Dec/2025
Minerva Neurosciences USD 1000 0 Sep/2024
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Pfizer USD 5.69B 1000K Sep/2025
Rigel Pharmaceuticals USD 17K 158K Jun/2024
United Therapeutics USD 43.64M 740K Dec/2025
Vanda Pharmaceuticals USD 58K 0 Dec/2024